S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Conditions
- Colon Adenocarcinoma
- ERBB2 Gene Amplification
- Rectal Adenocarcinoma
- Recurrent Colon Carcinoma
- Recurrent Rectal Carcinoma
- Stage III Colon Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7
- Stage IIIA Colon Cancer AJCC v7
- Stage IIIA Rectal Cancer AJCC v7
- Stage IIIB Colon Cancer AJCC v7
- Stage IIIB Rectal Cancer AJCC v7
- Stage IIIC Colon Cancer AJCC v7
- Stage IIIC Rectal Cancer AJCC v7
- Stage IV Colon Cancer AJCC v7
- Stage IV Rectal Cancer AJCC v7
- Stage IVA Colon Cancer AJCC v7
- Stage IVA Rectal Cancer AJCC v7
- Stage IVB Colon Cancer AJCC v7
- Stage IVB Rectal Cancer AJCC v7
Interventions
- BIOLOGICAL: Cetuximab
- DRUG: Irinotecan Hydrochloride
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pertuzumab
- BIOLOGICAL: Trastuzumab
- DEVICE: HER-2 testing
Sponsor
SWOG Cancer Research Network
Collaborators